论文部分内容阅读
目的 研究MAT1、nm2 3H1mRNA表达及突变与卵巢癌淋巴结转移的关系。 方法 应用逆转录 PCR(RT PCR)和逆转录 PCR 单链构像多态性分析 (RT PCR SSCP)技术 ,对 8例正常卵巢、2 0例卵巢癌及其相应的 2 0例淋巴结组织 ,进行MTA1和nm2 3H1mRNA表达及突变的检测。 结果 转移卵巢癌原发灶MTA1mRNA高表达率为 10 0 % (7/ 7) ,无转移为 38 5 % (5 / 13) ,P =0 0 10 3;有癌转移淋巴结高表达率为 87 5 % (6 / 7) ,无癌转移为 2 3 % (3/ 13) ,P =0 0 118。有转移卵巢癌原发灶nm2 3H1mRNA低表达率为 10 0 % (7/ 7) ,无转移为 30 % (4 / 13) ,P =0 0 0 43;有癌转移淋巴结低表达率为 10 0 %(7/ 7) ,无癌转移为 38 5 % (5 / 13) ,P =0 0 10 2。MTA1/nm2 3H1mRNA表达的相对吸光度值 (A值 ,曾称光密度OD值 )的比值随转移而增加。单链构像多态性分析 (SSCP)未发现突变。 结论 MTA1、nm2 3H1基因的转录表达与卵巢癌淋巴结转移呈正负相关关系 ,起着正负调控的重要作用。这两个基因的异常表达是卵巢癌转移中的频发事件而与基因突变无关。
Objective To study the relationship between MAT1, nm2 3H1 mRNA expression and lymph node metastasis in ovarian cancer. Methods Reverse transcription polymerase chain reaction (RT PCR) and Reverse Transcription Polymerase Chain Reaction (PCR) single strand conformation polymorphism (RT PCR SSCP) were performed in 8 normal ovarian tissues, 20 normal ovarian tissues and 20 corresponding lymph node tissues Detection of MTA1 and nm2 3H1 mRNA Expression and Mutation. Results The high expression rate of MTA1 mRNA in metastatic ovarian cancer was 10 0% (7/7), no metastasis was 38 5% (5/13), P 0 01 3 3, and the high expression rate of metastatic lymph node was 87 5 % (6/7), no cancer metastasis was 23% (3/13), P = 0 0 118. The low expression rate of nm23H1mRNA in metastatic ovarian cancer was 10 0% (7/7), no metastasis was 30% (4/13), P = 0 0 433. The low expression rate of metastatic lymph node was 10 % (7/7), no cancer metastasis was 38 5% (5/13), P = 0 0 10 2. The ratio of the relative absorbance value of the MTA1 / nm2 3H1 mRNA expression (A value, formerly known as the OD value of the optical density) increased with transfer. Single strand conformation polymorphism analysis (SSCP) No mutations were found. Conclusion The transcriptional expression of MTA1 and nm2 3H1 genes has a positive and negative correlation with lymph node metastasis of ovarian cancer, playing an important role in the regulation of both positive and negative. Abnormal expression of these two genes is a frequent event in ovarian cancer metastasis and has nothing to do with gene mutation.